Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease

Therapies to increase LRP1 expression or reduce RAGE activity at the BBB and/or restore the peripheral Aβ ‘sink’ action, hold potential to reduce brain Aβ and inflammation, and improve CBF and functional recovery in AD models, and by extension in AD patients.